Lactobacillus Gasseri for Weight Loss: What the Human Evidence Actually Shows

Lactobacillus gasseri is one of the few probiotic strains with multiple randomized human trials behind its weight management claims. The evidence is real, but its details matter considerably for anyone evaluating products based on it. Understanding what the studies actually measured, who they enrolled, and how they delivered the probiotic shapes what conclusions can reasonably be drawn.

The SBT2055 Clinical Evidence

The weight-loss evidence for L. gasseri belongs almost entirely to one specific strain: SBT2055. The primary trial is a 12-week, multicenter, double-blind, randomized, placebo-controlled study in 87 Japanese adults with higher body mass index (BMI) (24.2–30.7 kg/m²), in which participants consumed 200g per day of fermented milk either containing SBT2055 or without it.¹

Results in the active group, compared to control:

• Abdominal visceral fat area: −4.6% from baseline (P\<0.01)
• Subcutaneous fat area: −3.3% from baseline (P\<0.01)
• Body weight, BMI, and waist and hip circumferences: all significantly reduced

A follow-up trial enrolled 210 Japanese adults and tested whether the effects held at lower colony-forming unit (CFU) concentrations.² Both lower doses (10⁶ and 10⁷ cfu/g) produced significant reductions in abdominal visceral fat, confirming that the effect was not exclusive to the highest dose used in the original study.

Taken together, these are among the cleaner examples of strain-level, human, placebo-controlled evidence for visceral fat reduction in the probiotic literature.

What the Evidence Tells You About Choosing a Product

The SBT2055 trials are rigorous, but four details shape how that evidence applies to supplement selection.

1. The studied strain is SBT2055, not L. gasseri generically

Lactobacillus gasseri encompasses many strains with different properties and different evidence profiles. SBT2055 is the strain behind the abdominal fat data. Most commercial supplements labeled Lactobacillus gasseri do not specify which strain they contain, making it impossible to connect them to the SBT2055 research.

2. Both trials used fermented milk, not capsules

The delivery vehicle in both Kadooka studies was 200g of fermented milk per day. Fermented milk provides live bacteria in a buffered food matrix, with no acidic stomach environment to navigate in the same way a capsule does. Whether capsule-delivered SBT2055 reaches the gut in sufficient viable quantities to produce the same effect has not been tested in a body composition trial. This is a genuine gap between the published evidence and what most supplements deliver.

3. The population was Japanese adults

Both trials enrolled Japanese adults in a BMI range of 24.2–30.7 kg/m². This demographic may have different baseline gut microbiome composition and dietary context than Western populations. Extrapolating the effect size directly to other populations carries some uncertainty.

4. Effects were reversible after stopping

In the 2010 trial, abdominal fat areas recovered significantly during a 4-week washout period after the intervention ended. The results were contingent on continued consumption, not a sustained shift that persisted after discontinuation.

None of these limitations discredit the SBT2055 research. They are the honest reading of what the trials show, and they matter for setting realistic expectations.

Comparing the Evidence: SBT2055 and B420™

Researchers interested in strain-level human evidence for body fat endpoints have a second strain worth knowing: Bifidobacterium animalis ssp. lactis B420 (B420™). The two strains have different mechanisms, different trial designs, and different population profiles. A direct comparison is useful for anyone weighing their options.

| | | | |----|----|----| | | L. gasseri SBT2055 | B420™ | | Primary trial duration | 12 weeks | 6 months | | Primary trial N | 87 (2010); replicated in 210 (2013) | 225 | | Population | Japanese adults, BMI 24.2–30.7 | Adults aged 18–65, BMI 28.0–34.9 | | Delivery studied | Fermented milk | Supplement | | Visceral/body fat change | −4.6% visceral fat vs. control | −4.0% body fat mass vs. placebo | | Waist circumference | Significant reduction | −2.4 cm vs. placebo (~0.94 inch) | | Effect on discontinuation | Fat recovered during washout | Not assessed in this trial |

The B420™ data come from post-hoc factorial analysis within the 6-month randomized controlled trial (RCT), not a pre-specified primary outcome. This framing is important for interpreting the strength of the signal.³

B420™ was tested in a supplement format, its trials enrolled a broader Western-comparable population across a wider age range, and the 6-month duration exceeds the 12-week window of the SBT2055 studies. For people who arrived at L. gasseri through an interest in strain-level evidence for body composition, B420™ represents a parallel line of evidence with several practical advantages.

WONDERBIOTICS: Built Around B420™

WONDERBIOTICS does not contain L. gasseri SBT2055. Its core probiotic strain is B420™. The Probiotics for Weight Management formula is built around B420™ alongside Eriomin® (lemon extract), which has ingredient-level clinical research in prediabetic populations reporting support for natural glucagon-like peptide-1 (GLP-1) levels, and Dihydroberberine, a more bioavailable berberine-delivery route. The formula also features CraveLock™ Technology, a proprietary approach to appetite management and Food Noise.

For delivery, WONDERBIOTICS uses PolarSeal Technology to help protect the probiotic blend. In testing, 99.9% of the bacterial strain survived conditions simulating gut-like acidity, and 98.2% of the bacteria remained alive through the point of consumption.

The key ingredients behind the formula are backed by 624 clinical studies and 44,692 participants. The formula was developed by a team of PhD scientists and industry experts.

Choosing With the Evidence in Hand

If L. gasseri SBT2055 is specifically what you are looking for, the evidence supports it for abdominal visceral fat reduction in the studied population and delivery format. The practical challenge is finding a supplement that transparently identifies SBT2055 and has addressed the fermented milk-to-capsule translation question.

If the underlying goal is strain-level human evidence for body composition, B420™ is a strain worth evaluating alongside SBT2055. For B420™-based supplementation, we recommend a usage period of 3 to 6 months, to give your gut time to adapt and your body time to respond, alongside a nutritious diet and consistent physical activity.

Explore WONDERBIOTICS Probiotics for Weight Management

References

1. Kadooka Y, Sato M, Imaizumi K, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseriSBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 2010;64(6):636-643. https://www.nature.com/articles/ejcn201019
2. Kadooka Y, Sato M, Ogawa A, et al. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. Br J Nutr. 2013;110(9):1696-1703. https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effect-of-lactobacillus-gasseri-sbt2055-in-fermented-milk-on-abdominal-adiposity-in-adults-in-a-randomised-controlled-trial/304E3E2EE11E0D3D4F5D85E7046118A1
3. Stenman LK, Lehtinen MJ, Meland N, et al. Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults: randomized controlled trial. EBioMedicine. 2016;13:190-200. https://www.sciencedirect.com/science/article/pii/S2352396416304972